Targeted drugs and combination therapies can drive cancer into remission, as they achieve optimal
results in subsets of patients.
Not exact matches
If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer
patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could
result in a change
in the paradigm
of how a large
subset of locally advanced NSCLC
patients are treated.»
The drug — named mepolizumab — can replace traditional, steroid - based treatments for a specific
subset of patients,
resulting in improved outcomes and reduced side effects.
It was heterozygous
in most
patients, homozygous
in a
subset as a
result of mitotic recombination, and arose
in a multipotent progenitor capable
of giving rise to erythroid and myeloid cells.